Understanding the role of bacterial and fungal infection in COVID-19

Clinical Microbiology and Infection, Год журнала: 2020, Номер 27(1), С. 9 - 11

Опубликована: Окт. 9, 2020

Язык: Английский

---

Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative

JAMA Network Open, Год журнала: 2022, Номер 5(2), С. e2143151 - e2143151

Опубликована: Фев. 8, 2022

Importance

Understanding of SARS-CoV-2 infection in US children has been limited by the lack large, multicenter studies with granular data.

Objective

To examine characteristics, changes over time, outcomes, and severity risk factors within National COVID Cohort Collaborative (N3C).

Design, Setting, Participants

A prospective cohort study encounters end dates before September 24, 2021, was conducted at 56 N3C facilities throughout US. Participants included younger than 19 years initial testing.

Main Outcomes Measures

Case incidence demographic comorbidity factors, vital sign laboratory trajectories, clinical acute COVID-19 vs multisystem inflammatory syndrome (MIS-C), Delta pre-Delta variant differences for SARS-CoV-2.

Results

total 1 068 410 were tested 167 262 test results (15.6%) positive (82 882 [49.6%] girls; median age, 11.9 [IQR, 6.0-16.1] years). Among 10 245 (6.1%) who hospitalized, 1423 (13.9%) met criteria severe disease: mechanical ventilation (796 [7.8%]), vasopressor-inotropic support (868 [8.5%]), extracorporeal membrane oxygenation (42 [0.4%]), or death (131 [1.3%]). Male sex (odds ratio [OR], 1.37; 95% CI, 1.21-1.56), Black/African American race (OR, 1.25; 1.06-1.47), obesity 1.19; 1.01-1.41), several pediatric complex chronic condition (PCCC) subcategories associated higher disease. Vital signs many values from day admission predictive peak disease severity. Variables increased odds MIS-C male 1.59; 1.33-1.90), 1.44; 1.17-1.77), 12 1.81; 1.51-2.18), 1.76; 1.40-2.22), not having a 0.72; 0.65-0.80). The had more profile phenotype, rates invasive (117 707 [16.5%] 514 8241 [6.2%];P < .001) need vasoactive-inotropic (191 [27.0%] 426 [5.2%];P compared those COVID-19. Comparing during eras, there no significant change hospitalization rate (1738 [6.0%] 8507 = .18) lower (179 [10.3%] 1242 [14.6%]) (decreased factor 0.67; 0.57-0.79;P .001).

Conclusions Relevance

In this SARS-CoV-2, observed preexisting comorbidities, between subgroups. Taken together, these suggest that early identification likely to progress could be achieved using readily available data elements admission. Further work is needed translate knowledge into improved outcomes.

Язык: Английский

---

Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit

Infection, Год журнала: 2021, Номер 50(1), С. 83 - 92

Опубликована: Июнь 27, 2021

Superinfections in patients hospitalized intensive care unit (ICU) are an important and challenging complication, also COVID-19. However, no definitive data available about the role of multidrug-resistant Acinetobacter baumannii (MDR-AB) COVID-19.This was a single-center, cross-sectional study including with MDR-AB infections admitted to ICU or without COVID-19, between January 2019 2021. The primary objective evaluate risk factor for COVID-19 other etiology. secondary endpoints were 30-days mortality all population factors associated development bloodstream infection (BSI).During period 32 adults enrolled compared 115 same reasons. We observed total 114 deaths, survival rate 29.3%: 18.8% 32.2% control group. Relative showed that serum lactate levels mmol/l > 2, colonization, BSI steroid therapy more frequently patients. Cox regression analysis 2 mmol/l, BSI, mortality. Finally, white blood cells count 11,000 mm3, at time admission, independently BSI.Our highlight impact on outcome, colonization use steroids develop during

Язык: Английский

---

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)

Clinical Infectious Diseases, Год журнала: 2022, Номер 78(7), С. e250 - e349

Опубликована: Сен. 5, 2022

Abstract There are many pharmacologic therapies that being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living guidelines intended support patients, clinicians, other healthcare professionals in their decisions about management patients COVID-19. In March 2020, the Infectious Diseases Society America (IDSA) formed a multidisciplinary guideline panel infectious pharmacists, methodologists varied areas expertise regularly review make recommendations persons process approach followed rapid recommendation development checklist. prioritized questions outcomes. A systematic peer-reviewed grey literature conducted at regular intervals. Grading Recommendations Assessment, Development, Evaluation (GRADE) assess certainty recommendations. Based on most recent search 31 May 2022, IDSA has made 32 following groups/populations: pre- postexposure prophylaxis, ambulatory mild-to-moderate disease, hospitalized mild-to-moderate, severe but not critical, critical disease. As these guidelines, can be found online at: https://idsociety.org/COVID19guidelines. At inception its work, expressed overarching goal recruited into ongoing Since then, trials were provided much-needed COVID-19 therapies. still remain unanswered as pandemic evolved, which we hope future answer.

Язык: Английский

---

COVID-19 and antimicrobial resistance: A cross-study

The Science of The Total Environment, Год журнала: 2021, Номер 807, С. 150873 - 150873

Опубликована: Окт. 9, 2021

Язык: Английский

---